TOP2A is involved in many cancers, being a prognostic biomarker and potential therapeutic target for bladder cancer, lung adenocarcinoma, prostate cancer, colon cancer, breast cancer, and HCC [144,145]. This evidence concerns the gene TOP2A and prostate carcinoma.